---
title: "SciSparc Ltd. (SPRC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SPRC.US.md"
symbol: "SPRC.US"
name: "SciSparc Ltd."
industry: "Pharmaceuticals"
datetime: "2026-06-13T18:42:24.008Z"
locales:
  - [en](https://longbridge.com/en/quote/SPRC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPRC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPRC.US.md)
---

# SciSparc Ltd. (SPRC.US)

## Company Overview

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [cisparc.com](https://cisparc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:14.000Z

**Overall: D (0.73)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 166 / 196 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -34.46% |  |
| Net Profit YoY | -93.81% |  |
| P/B Ratio | 1.14 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4835025.00 |  |
| Revenue | 856000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -196.55% | E |
| Profit Margin | -1422.78% | E |
| Gross Margin | 73.71% | A |
| Revenue YoY | -34.46% | E |
| Net Profit YoY | -93.81% | E |
| Total Assets YoY | -26.34% | E |
| Net Assets YoY | -42.42% | E |
| Cash Flow Margin | 33.97% | D |
| OCF YoY | -34.46% | E |
| Turnover | 0.10 | E |
| Gearing Ratio | 32.47% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - SciSparc Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-34.46%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4835025.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "856000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-196.55%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1422.78%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "73.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-34.46%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.81%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-26.34%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-42.42%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "33.97%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-34.46%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.47%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.40 | 76/196 | - | - | - |
| PB | 1.14 | 55/196 | 0.66 | 0.43 | 0.28 |
| PS (TTM) | 5.65 | 100/196 | 3.66 | 2.65 | 1.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2022-04-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.55 |
| Highest Target | 98280.21 |
| Lowest Target | 98280.21 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SPRC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SPRC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SPRC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SPRC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**